

FOR IMMEDIATE RELEASE

BioFluidica to Introduce Next-Generation Biomarker Isolation Platform

LiquidScan™ at the 2022 American Association for Cancer Research Meeting in New Orleans

BioFluidica LiquidScan Harnesses the Power of Microfluidics

SAN DIEGO, April 5, 2022 - Biofluidica today announced they will be introducing their new biomarker isolation platform, LiquidScan™, at the annual AACR Conference on April 10-13 in New Orleans. The novel platform isolates and enriches biomarker population directly from a blood draw replacing the need for surgical biopsies and making testing available for cancer types not previously amenable to surgical biopsy.

LiquidScan harnesses the power of microfluidics to isolate and enrich the three main categories of biomarkers from whole blood: rare cells, for example circulating tumor cells (CTCs) and fetal cells, exosomes, cfDNA, as well as infectious disease agents.

"LiquidScan is a novel platform that enhances the ability to perform diagnostic testing applied to many diseases, including several types of cancer, prenatal diagnostics, stroke, and infectious diseases," said Rolf Muller, BioFluidica CEO. "Our technology is automated allowing for high-throughput and the lower-cost testing than current surgical biopsy procedures. There is a win-win scenario here for patients, physicians, and the health-care system. Because LiquidScan uses a standard 10 ml blood draw, non-invasive screening, patients can receive closer monitoring of treatment regimens, physicians can attain higher quality and earlier patient results. Expensive and time-consuming surgical procedures can be removed from the health-care system".

LiquidScan, does not require cold storage of samples. The development of patented microfluidic chips allows for this leap in technological advantages, enabling improved commercial research diagnostics at lower costs. The chip offers efficient capture, release, and enumeration of key biomarkers and enabling downstream molecular analysis.

Muller continued, "Our hope with LiquidScan is to be able to facilitate and revolutionize early disease diagnosis and management. Thanks to its flexibility, LiquidScan can be readily adapted for several applications. The platform is ideal for those applications where the ability to conduct frequent tests inexpensively and deliver results quickly for point-of-care testing is critical."

About BioFluidica

BioFluidica Inc., is a privately held biotechnology company that has developed a revolutionary liquid biopsy platform. x. For more information please visit <https://www.biofluidica.com/>

Business Development Contact:

Brent Keller

FOR IMMEDIATE RELEASE

brent.keller@biofluidica.com

Media Contact:

Julie Ferguson

media@biofluidica.com

(312) 385-0098